New gold nanoparticle vaccine aims to outsmart COVID-19 variants
NCT ID NCT07183709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new type of COVID-19 booster vaccine called PepGNP-COVID19. It uses tiny gold nanoparticles to train the immune system's T cells to recognize and fight the virus. The study involves 60 healthy adults aged 18-64 who will receive one of three doses to check safety and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PepGNP-COVID19 (a synthetic nanoparticle-based T-cell priming peptide vaccine)
What this could lead to
If successful, this could lead to a COVID-19 booster that provides broader and longer-lasting protection, potentially reducing the need for frequent vaccine updates.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so safety and immune response are still being tested. It may not prove effective or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037-3201, United States
-
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama, 35222, United States